PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases

JOURNAL ARTICLE published 15 September 2018 in Terapevticheskii arkhiv

Authors: V Z Lankin | A K Tikhaze | M Viigimaa | I E Chazova